|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
39,660,000 |
Market
Cap: |
100.74(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$1.12 - $3.19 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Eledon Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing targeted medicines for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with amyotrophic lateral sclerosis. Co.'s lead compound in development is AT-1501, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a biological target. AT-1501 is engineered to improve safety and provide pharmacokinetic, pharmacodynamic and dosing advantages. By blocking CD40L and not the CD40 receptor, AT-1501 inhibits both the CD40 and CD11 costimulatory signaling pathways, providing the potential for improved efficacy compared to anti-CD40 receptor approaches.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
1,927,937 |
1,927,937 |
3,907,869 |
Total Buy Value |
$0 |
$0 |
$0 |
$2,597 |
Total People Bought |
0 |
1 |
1 |
2 |
Total Buy Transactions |
0 |
1 |
1 |
3 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Satter Muneer A |
10% Owner |
|
2014-09-22 |
4 |
A |
$0.00 |
$0 |
I/I |
1,621,688 |
1,621,688 |
|
- |
|
Apple Tree Partners Ii Lp |
Director |
|
2014-09-22 |
4 |
A |
$0.00 |
$0 |
D/D |
4,218,632 |
4,218,641 |
|
- |
|
Novartis Ag |
10% Owner |
|
2014-09-22 |
4 |
B |
$15.00 |
$4,875,000 |
D/D |
325,000 |
4,644,328 |
2.45 |
- |
|
Novartis Ag |
10% Owner |
|
2014-09-22 |
4 |
A |
$0.00 |
$0 |
D/D |
4,319,328 |
4,319,328 |
|
- |
|
Harrison Seth Loring |
Director |
|
2014-09-22 |
4 |
B |
$15.00 |
$5,437,500 |
I/I |
362,500 |
7,912,079 |
2.25 |
- |
|
Harrison Seth Loring |
Director |
|
2014-09-22 |
4 |
A |
$0.00 |
$0 |
I/I |
7,549,570 |
7,549,579 |
|
- |
|
Barberich Timothy J |
Director |
|
2014-09-22 |
4 |
A |
$0.00 |
$0 |
D/D |
121,077 |
121,077 |
|
- |
|
Kalowski Lee |
Chief Financial Officer |
|
2014-09-17 |
4 |
A |
$0.00 |
$0 |
D/D |
54,604 |
54,604 |
|
- |
|
Apple Tree Partners Ii Lp |
10% Owner |
|
2014-09-16 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
9 |
|
- |
|
Williams Martin D |
10% Owner |
|
2014-09-16 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
168,850 |
|
- |
|
Harrison Seth Loring |
Director |
|
2014-09-16 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
9 |
|
- |
|
Harrison Seth Loring |
Director |
|
2014-09-16 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
212,694 |
|
- |
|
Yanchik Joseph A. Iii |
Director |
|
2014-09-16 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
25,546 |
|
- |
|
Morrison Jodie Pope |
President and CEOOfficer |
|
2014-09-16 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
9,551 |
|
- |
|
Novartis Ag |
10% Owner |
|
2014-06-15 |
4 |
S |
$14.20 |
$209,833 |
D/D |
(14,777) |
4,546,616 |
|
- |
|
90 Records found
|
|
Page 4 of 4 |
|
|